Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Can Bcl-XL expression predict the radio sensitivity of Bilharzial-related squamous bladder carcinoma? a prospective comparative study

Authors: Ahmad M Abdel Raheem, Diaa A Hameed, Ehab O ElGanainy, Eman Mosad, Mostafa E Abdelwanis, Nermen A Kamel, Hisham M Hammouda, Mohammad A Abdelaziz, Khaled Hemeyda

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Local pelvic recurrence after radical cystectomy for muscle invasive bilharzial related squamous cell carcinoma accounts for 75% of treatment failures even in organ confined tumors. Despite the proven value of lymphadenectomy, up to 60% of patients undergoing cystectomy do not have it. These factors are in favor of adjuvant radiotherapy reevaluation. objectives: to evaluate the effect of adjuvant radiotherapy on disease free survival in muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder and to test the predictability of radio-sensitivity using the anti apoptotic protein Bcl-XL.

Methods

The study prospectively included 71 patients, (47 males, 24 females) with muscle invasive bilharzial related squamous cell carcinoma of the bladder (Stage pT2a-T3N0-N3M0) who underwent radical cystectomy in Assiut university hospitals between January 2005 and December 2006. Thirty eight patients received adjuvant radiotherapy to the pelvis in the dose of 50Gy/25 fractions/5 weeks (Group 1), while 33 patients did not receive adjuvant radiotherapy (group 2). Immunohistochemical characterization for bcl-xL expression was done. Follow up was done every 3 months for 12 to 36 months with a mean of 16 ± 10 months. All data were analyzed using SPSS version 16. Three years cumulative disease free survival was calculated and adjusted to Bcl-XL expression and side effects of the treatment were recorded.

Results

The disease free cumulative survival was 48% for group 1 and 29% for group 2 (log rank p value 0.03). The multivariate predictors of tumor recurrence were the positive Bcl-XL expression (odd ratio 41.1, 95% CI 8.4 - 102.3, p < 0.0001) and radiotherapy (odd ratio 0.19, 95% CI 0.05 - 0.78, p < 0.02). With Cox regression, the only independent multivariate predictor of radio-sensitivity was the Bcl-XL expression with odd ratio 4.6 and a p value < 0.0001. All patients tolerated the treatment with no life threatening or late complications during the period of follow up.

Conclusions

Adjuvant radiotherapy for muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder has potential effectiveness and minor side effects. Moreover, Bcl-XL expression is a valuable tool for predicting those who might not respond to this adjuvant treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shokeir AA, Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment. BJU Int. 2004, 93 (2): 216-20. 10.1111/j.1464-410X.2004.04588.x.CrossRefPubMed Shokeir AA, Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment. BJU Int. 2004, 93 (2): 216-20. 10.1111/j.1464-410X.2004.04588.x.CrossRefPubMed
2.
go back to reference Ghoneim M, El-Mekresh M, El-Baz M, El-Attar I, Ashamallah A: Radical cystectomy for carcinoma of the bladder. Critical evaluation of the results in 1026 cases. J Urol. 1997, 158: 393-9. 10.1016/S0022-5347(01)64487-2.CrossRefPubMed Ghoneim M, El-Mekresh M, El-Baz M, El-Attar I, Ashamallah A: Radical cystectomy for carcinoma of the bladder. Critical evaluation of the results in 1026 cases. J Urol. 1997, 158: 393-9. 10.1016/S0022-5347(01)64487-2.CrossRefPubMed
3.
go back to reference Zarzour AH, Selim M, Abd-Elsayed AA, Hameed DA, AbdelAziz MA: Muscle invasive bladder cancer in Upper Egypt: the shift in risk factors and tumor characteristics. BMC Cancer. 2008, 8: 250-10.1186/1471-2407-8-250.CrossRefPubMedPubMedCentral Zarzour AH, Selim M, Abd-Elsayed AA, Hameed DA, AbdelAziz MA: Muscle invasive bladder cancer in Upper Egypt: the shift in risk factors and tumor characteristics. BMC Cancer. 2008, 8: 250-10.1186/1471-2407-8-250.CrossRefPubMedPubMedCentral
4.
go back to reference Khaled HM: Bladder cancer and bilharziasis today. Cancer J. 1993, 6: 65-71. Khaled HM: Bladder cancer and bilharziasis today. Cancer J. 1993, 6: 65-71.
5.
go back to reference Murthy V, Zaghloul MS: Adjuvant radiotherapy in bladder cancer: Time to take a fresh look?. Urol Oncol. 2007, 25: 353-4.CrossRefPubMed Murthy V, Zaghloul MS: Adjuvant radiotherapy in bladder cancer: Time to take a fresh look?. Urol Oncol. 2007, 25: 353-4.CrossRefPubMed
6.
go back to reference Darzynkiewicz Z: Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem. 1995, 58: 151-9. 10.1002/jcb.240580204.CrossRefPubMed Darzynkiewicz Z: Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. J Cell Biochem. 1995, 58: 151-9. 10.1002/jcb.240580204.CrossRefPubMed
7.
go back to reference Cheng E, Levine B, Boise L, Thompson C, Hardwick J: BAX-independent inhibition of apoptosis by Bcl-XL. Nature. 1996, 379: 554-6. 10.1038/379554a0.CrossRefPubMed Cheng E, Levine B, Boise L, Thompson C, Hardwick J: BAX-independent inhibition of apoptosis by Bcl-XL. Nature. 1996, 379: 554-6. 10.1038/379554a0.CrossRefPubMed
8.
go back to reference Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M: Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol. 2002, 56: 43-9. 10.1023/A:1014448721327.CrossRefPubMed Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M: Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol. 2002, 56: 43-9. 10.1023/A:1014448721327.CrossRefPubMed
9.
go back to reference Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA, Kufe D: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995, 6: 363-70.PubMed Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA, Kufe D: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995, 6: 363-70.PubMed
10.
go back to reference Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y, Imamura M: Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer. 1999, 35: 1374-80. 10.1016/S0959-8049(99)00134-3.CrossRefPubMed Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y, Imamura M: Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer. 1999, 35: 1374-80. 10.1016/S0959-8049(99)00134-3.CrossRefPubMed
11.
go back to reference Hameed DA, Abdel Raheem AM, Mosad E, Hammouda HM, Kamel NA, Abdel Aziz MA: Bcl-XL and Bcl-2 Expression in Bilharzial Squamous Cell Carcinoma of the Urinary Bladder: Which Protein Is Prognostic?. UROLOGY. 2008, 72: 374-378. 10.1016/j.urology.2007.12.063.CrossRefPubMed Hameed DA, Abdel Raheem AM, Mosad E, Hammouda HM, Kamel NA, Abdel Aziz MA: Bcl-XL and Bcl-2 Expression in Bilharzial Squamous Cell Carcinoma of the Urinary Bladder: Which Protein Is Prognostic?. UROLOGY. 2008, 72: 374-378. 10.1016/j.urology.2007.12.063.CrossRefPubMed
12.
go back to reference Bethesda Md: Common Toxicity Criteria Manual. 1999, National Cancer Institute Bethesda Md: Common Toxicity Criteria Manual. 1999, National Cancer Institute
13.
go back to reference Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, El-Attar I: Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992, 23: 511-7. 10.1016/0360-3016(92)90005-3.CrossRefPubMed Zaghloul MS, Awwad HK, Akoush HH, Omar S, Soliman O, El-Attar I: Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992, 23: 511-7. 10.1016/0360-3016(92)90005-3.CrossRefPubMed
14.
go back to reference Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J Clin Oncol. 2001, 19: 666-75.PubMed Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J Clin Oncol. 2001, 19: 666-75.PubMed
15.
go back to reference Konety BR, Joslyn SA, O'Donnel MA: Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the surveillance, epidemiology, and end results (SEER) program database. J Urol. 2003, 169: 945-50. 10.1097/01.ju.0000052721.61645.a3.CrossRef Konety BR, Joslyn SA, O'Donnel MA: Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the surveillance, epidemiology, and end results (SEER) program database. J Urol. 2003, 169: 945-50. 10.1097/01.ju.0000052721.61645.a3.CrossRef
16.
go back to reference Kaufman D, Shipley W, Feldman A: Bladder cancer. Lancet. 2009, 374 (9685): 239-249. 10.1016/S0140-6736(09)60491-8.CrossRefPubMed Kaufman D, Shipley W, Feldman A: Bladder cancer. Lancet. 2009, 374 (9685): 239-249. 10.1016/S0140-6736(09)60491-8.CrossRefPubMed
17.
go back to reference Reisinger S, Mohiuddin M, Mulholland S: Combined pre- and postoperative adjuvant radiation therapy for bladder cancer--a ten years experience. Int J Radiat Oncol Biol Phys. 1992, 24: 463-8. 10.1016/0360-3016(92)91060-Z.CrossRefPubMed Reisinger S, Mohiuddin M, Mulholland S: Combined pre- and postoperative adjuvant radiation therapy for bladder cancer--a ten years experience. Int J Radiat Oncol Biol Phys. 1992, 24: 463-8. 10.1016/0360-3016(92)91060-Z.CrossRefPubMed
18.
go back to reference Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, Khalil E: Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients. Urol Oncol. 2006, 24: 13-20.CrossRefPubMed Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, Khalil E: Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients. Urol Oncol. 2006, 24: 13-20.CrossRefPubMed
20.
go back to reference Kojima H, Endo K, Moriyama H, Tanaka Y, Alnemri ES, Slapak CA, Teicher B, Kufe D, Datta R: Abrogation of mitochondrial cytochrome-C release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 1998, 272: 16647-50. 10.1074/jbc.273.27.16647.CrossRef Kojima H, Endo K, Moriyama H, Tanaka Y, Alnemri ES, Slapak CA, Teicher B, Kufe D, Datta R: Abrogation of mitochondrial cytochrome-C release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 1998, 272: 16647-50. 10.1074/jbc.273.27.16647.CrossRef
21.
go back to reference Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Bartelink H, Verheij M: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol. 2001, 61: 169-75. 10.1016/S0167-8140(01)00421-2.CrossRefPubMed Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Bartelink H, Verheij M: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol. 2001, 61: 169-75. 10.1016/S0167-8140(01)00421-2.CrossRefPubMed
Metadata
Title
Can Bcl-XL expression predict the radio sensitivity of Bilharzial-related squamous bladder carcinoma? a prospective comparative study
Authors
Ahmad M Abdel Raheem
Diaa A Hameed
Ehab O ElGanainy
Eman Mosad
Mostafa E Abdelwanis
Nermen A Kamel
Hisham M Hammouda
Mohammad A Abdelaziz
Khaled Hemeyda
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-16

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine